Skip to main content
main-content
Erschienen in: Die Gastroenterologie 5/2022

01.07.2022 | Leberzirrhose | CME

Medikamentöse Therapie bei Patienten mit Leberzirrhose

Aktueller Stand und zukünftige Entwicklungen

verfasst von: Najib Ben Khaled, Julian Allgeier, Teresa Lutz, Sabine Weber, Prof. Dr. med. Christian M. Lange

Erschienen in: Die Gastroenterologie | Ausgabe 5/2022

zum CME-Kurs Einloggen, um Zugang zu erhalten

Zusammenfassung

Die Leberzirrhose ist das Endstadium chronischer Lebererkrankungen und insbesondere im fortgeschrittenen Stadium mit einer hohen Morbidität und Mortalität verbunden. Patienten mit Leberfunktionseinschränkung sind permanent von einer Vielzahl schwerwiegender Komplikationen bedroht. Ein optimales pharmakologisches Management bei Patienten mit Leberinsuffizienz kann die Progression der Grunderkrankung verlangsamen, Hospitalisationen verhindern sowie Lebensqualität und Überleben verbessern. Dieser Artikel gibt einen Überblick über den aktuellen Stand und neue Entwicklungen der Pharmakotherapie bei Patienten mit Leberzirrhose.
Literatur
1.
Zurück zum Zitat Sepanlou SG, Safiri S, Bisignano C et al (2020) The global, regional, and national burden of cirrhosis by cause in 195 countries and territories, 1990–2017: a systematic analysis for the global burden of disease study 2017. Lancet Gastroenterol Hepatol 5:245–266 CrossRef Sepanlou SG, Safiri S, Bisignano C et al (2020) The global, regional, and national burden of cirrhosis by cause in 195 countries and territories, 1990–2017: a systematic analysis for the global burden of disease study 2017. Lancet Gastroenterol Hepatol 5:245–266 CrossRef
2.
Zurück zum Zitat Weersink RA, Taxis K, Drenth JPH et al (2019) Prevalence of drug prescriptions and potential safety in patients with cirrhosis: a retrospective real-world study. Drug Saf 42:539–546 CrossRef Weersink RA, Taxis K, Drenth JPH et al (2019) Prevalence of drug prescriptions and potential safety in patients with cirrhosis: a retrospective real-world study. Drug Saf 42:539–546 CrossRef
3.
Zurück zum Zitat D’amico G, Garcia-Tsao G, Pagliaro L (2006) Natural history and prognostic indicators of survival in cirrhosis: a systematic review of 118 studies. J Hepatol 44:217–231 CrossRef D’amico G, Garcia-Tsao G, Pagliaro L (2006) Natural history and prognostic indicators of survival in cirrhosis: a systematic review of 118 studies. J Hepatol 44:217–231 CrossRef
4.
Zurück zum Zitat Gerbes AL, Labenz J, Appenrodt B et al (2019) Updated S2k-guideline “complications of liver cirrhosis”. German society of gastroenterology (DGVS). Z Gastroenterol 57:611–680 CrossRef Gerbes AL, Labenz J, Appenrodt B et al (2019) Updated S2k-guideline “complications of liver cirrhosis”. German society of gastroenterology (DGVS). Z Gastroenterol 57:611–680 CrossRef
5.
Zurück zum Zitat Caraceni P, Riggio O, Angeli P et al (2018) Long-term albumin administration in decompensated cirrhosis (ANSWER): an open-label randomised trial. Lancet 391:2417–2429 CrossRef Caraceni P, Riggio O, Angeli P et al (2018) Long-term albumin administration in decompensated cirrhosis (ANSWER): an open-label randomised trial. Lancet 391:2417–2429 CrossRef
6.
Zurück zum Zitat Angeli P, Gines P, Wong F et al (2015) Diagnosis and management of acute kidney injury in patients with cirrhosis: revised consensus recommendations of the international club of ascites. J Hepatol 62:968–974 CrossRef Angeli P, Gines P, Wong F et al (2015) Diagnosis and management of acute kidney injury in patients with cirrhosis: revised consensus recommendations of the international club of ascites. J Hepatol 62:968–974 CrossRef
7.
Zurück zum Zitat European Association for the Study of the Liver (2018) EASL clinical practice guidelines for the management of patients with decompensated cirrhosis. J Hepatol 69:406–460 CrossRef European Association for the Study of the Liver (2018) EASL clinical practice guidelines for the management of patients with decompensated cirrhosis. J Hepatol 69:406–460 CrossRef
8.
Zurück zum Zitat Wong F, Pappas SC, Curry MP et al (2021) Terlipressin plus albumin for the treatment of type 1 hepatorenal syndrome. N Engl J Med 384:818–828 CrossRef Wong F, Pappas SC, Curry MP et al (2021) Terlipressin plus albumin for the treatment of type 1 hepatorenal syndrome. N Engl J Med 384:818–828 CrossRef
9.
Zurück zum Zitat Wong F, Pappas SC, Reddy KR et al (2021) Increased incidence of respiratory failure with terlipressin use in patients with hepatorenal syndrome type 1 & severe acute-on-chronic liver failure. The international liver congress Wong F, Pappas SC, Reddy KR et al (2021) Increased incidence of respiratory failure with terlipressin use in patients with hepatorenal syndrome type 1 & severe acute-on-chronic liver failure. The international liver congress
10.
Zurück zum Zitat Rudler M, Weiss N, Bouzbib C et al (2021) Diagnosis and management of hepatic encephalopathy. Clin Liver Dis 25:393–417 CrossRef Rudler M, Weiss N, Bouzbib C et al (2021) Diagnosis and management of hepatic encephalopathy. Clin Liver Dis 25:393–417 CrossRef
11.
Zurück zum Zitat Gluud LL, Vilstrup H, Morgan MY (2016) Non-absorbable disaccharides versus placebo/no intervention and lactulose versus lactitol for the prevention and treatment of hepatic encephalopathy in people with cirrhosis. Cochrane Database Syst Rev 4:CD3044 PubMed Gluud LL, Vilstrup H, Morgan MY (2016) Non-absorbable disaccharides versus placebo/no intervention and lactulose versus lactitol for the prevention and treatment of hepatic encephalopathy in people with cirrhosis. Cochrane Database Syst Rev 4:CD3044 PubMed
12.
Zurück zum Zitat Bass NM, Mullen KD, Sanyal A et al (2010) Rifaximin treatment in hepatic encephalopathy. N Engl J Med 362:1071–1081 CrossRef Bass NM, Mullen KD, Sanyal A et al (2010) Rifaximin treatment in hepatic encephalopathy. N Engl J Med 362:1071–1081 CrossRef
13.
Zurück zum Zitat Sidhu SS, Sharma BC, Goyal O et al (2018) L‑ornithine L‑aspartate in bouts of overt hepatic encephalopathy. Hepatology 67:700–710 CrossRef Sidhu SS, Sharma BC, Goyal O et al (2018) L‑ornithine L‑aspartate in bouts of overt hepatic encephalopathy. Hepatology 67:700–710 CrossRef
14.
Zurück zum Zitat Butterworth RF, Mcphail MJW (2019) L‑ornithine L‑aspartate (LOLA) for hepatic encephalopathy in cirrhosis: results of randomized controlled trials and meta-analyses. Drugs 79:31–37 CrossRef Butterworth RF, Mcphail MJW (2019) L‑ornithine L‑aspartate (LOLA) for hepatic encephalopathy in cirrhosis: results of randomized controlled trials and meta-analyses. Drugs 79:31–37 CrossRef
15.
Zurück zum Zitat Bajaj JS, Fagan A, Gavis EA et al (2019) Long-term outcomes of fecal microbiota transplantation in patients with cirrhosis. Gastroenterology 156:1921–1923.e3 CrossRef Bajaj JS, Fagan A, Gavis EA et al (2019) Long-term outcomes of fecal microbiota transplantation in patients with cirrhosis. Gastroenterology 156:1921–1923.e3 CrossRef
16.
Zurück zum Zitat Ripoll C, Groszmann R, Garcia-Tsao G et al (2007) Hepatic venous pressure gradient predicts clinical decompensation in patients with compensated cirrhosis. Gastroenterology 133:481–488 CrossRef Ripoll C, Groszmann R, Garcia-Tsao G et al (2007) Hepatic venous pressure gradient predicts clinical decompensation in patients with compensated cirrhosis. Gastroenterology 133:481–488 CrossRef
17.
Zurück zum Zitat Götz M, Anders M, Biecker E et al (2017) S2k guideline gastrointestinal bleeding—guideline of the German society of gastroenterology DGVS. Z Gastroenterol 55:883–936 CrossRef Götz M, Anders M, Biecker E et al (2017) S2k guideline gastrointestinal bleeding—guideline of the German society of gastroenterology DGVS. Z Gastroenterol 55:883–936 CrossRef
18.
Zurück zum Zitat Gluud LL, Krag A (2012) Banding ligation versus beta-blockers for primary prevention in oesophageal varices in adults. Cochrane Database Syst Rev 8:CD4544 Gluud LL, Krag A (2012) Banding ligation versus beta-blockers for primary prevention in oesophageal varices in adults. Cochrane Database Syst Rev 8:CD4544
20.
Zurück zum Zitat Villanueva C, Albillos A, Genesca J et al (2019) beta blockers to prevent decompensation of cirrhosis in patients with clinically significant portal hypertension (PREDESCI): a randomised, double-blind, placebo-controlled, multicentre trial. Lancet 393:1597–1608 CrossRef Villanueva C, Albillos A, Genesca J et al (2019) beta blockers to prevent decompensation of cirrhosis in patients with clinically significant portal hypertension (PREDESCI): a randomised, double-blind, placebo-controlled, multicentre trial. Lancet 393:1597–1608 CrossRef
21.
Zurück zum Zitat Ambrosino P, Tarantino L, Di Minno G et al (2017) The risk of venous thromboembolism in patients with cirrhosis. A systematic review and meta-analysis. Thromb Haemost 117:139–148 CrossRef Ambrosino P, Tarantino L, Di Minno G et al (2017) The risk of venous thromboembolism in patients with cirrhosis. A systematic review and meta-analysis. Thromb Haemost 117:139–148 CrossRef
22.
Zurück zum Zitat Villa E, Camma C, Marietta M et al (2012) Enoxaparin prevents portal vein thrombosis and liver decompensation in patients with advanced cirrhosis. Gastroenterology 143:1253–1260.e4 CrossRef Villa E, Camma C, Marietta M et al (2012) Enoxaparin prevents portal vein thrombosis and liver decompensation in patients with advanced cirrhosis. Gastroenterology 143:1253–1260.e4 CrossRef
23.
Zurück zum Zitat Loffredo L, Pastori D, Farcomeni A et al (2017) Effects of anticoagulants in patients with cirrhosis and portal vein thrombosis: a systematic review and meta-analysis. Gastroenterology 153:480–487.e1 CrossRef Loffredo L, Pastori D, Farcomeni A et al (2017) Effects of anticoagulants in patients with cirrhosis and portal vein thrombosis: a systematic review and meta-analysis. Gastroenterology 153:480–487.e1 CrossRef
24.
Zurück zum Zitat Lee ZY, Suah BH, Teo YH et al (2022) Comparison of the efficacy and safety of direct oral anticoagulants and vitamin K antagonists in patients with atrial fibrillation and concomitant liver cirrhosis: a systematic review and meta-analysis. Am J Cardiovasc Drugs 22(2):157–165 CrossRef Lee ZY, Suah BH, Teo YH et al (2022) Comparison of the efficacy and safety of direct oral anticoagulants and vitamin K antagonists in patients with atrial fibrillation and concomitant liver cirrhosis: a systematic review and meta-analysis. Am J Cardiovasc Drugs 22(2):157–165 CrossRef
25.
Zurück zum Zitat Terrault N, Chen YC, Izumi N et al (2018) Avatrombopag before procedures reduces need for platelet transfusion in patients with chronic liver disease and thrombocytopenia. Gastroenterology 155:705–718 CrossRef Terrault N, Chen YC, Izumi N et al (2018) Avatrombopag before procedures reduces need for platelet transfusion in patients with chronic liver disease and thrombocytopenia. Gastroenterology 155:705–718 CrossRef
26.
Zurück zum Zitat Peck-Radosavljevic M, Simon K, Iacobellis A et al (2019) Lusutrombopag for the treatment of thrombocytopenia in patients with chronic liver disease undergoing invasive procedures (L-PLUS 2). Hepatology 70:1336–1348 CrossRef Peck-Radosavljevic M, Simon K, Iacobellis A et al (2019) Lusutrombopag for the treatment of thrombocytopenia in patients with chronic liver disease undergoing invasive procedures (L-PLUS 2). Hepatology 70:1336–1348 CrossRef
Metadaten
Titel
Medikamentöse Therapie bei Patienten mit Leberzirrhose
Aktueller Stand und zukünftige Entwicklungen
verfasst von
Najib Ben Khaled
Julian Allgeier
Teresa Lutz
Sabine Weber
Prof. Dr. med. Christian M. Lange
Publikationsdatum
01.07.2022

Weitere Artikel der Ausgabe 5/2022

Die Gastroenterologie 5/2022 Zur Ausgabe

Mitteilungen der Stiftung LebensBlicke

Mitteilungen der Stiftung LebensBlicke

Mitteilungen der Gesellschaft für Gastroenterologie in NRW

Mitteilungen der Gesellschaft für Gastroenterologie in NRW

Schwerpunkt

Sarkoidose

Mitteilungen der GARPS

Mitteilungen der GARPS